July 21, 2006 -- Amylin traded lower after Q2 revenues for Byetta were lower than expected; Lilly and Alcon will co-promote Arxxant, an oral drug that treats diabetic retinopathy; MedImmune highlighted a new anti-cancer molecule that was developed in collaboration with Micromet; Berlex recalled a single lot of its X-ray contrast agent, Ultravist Injection; Shire submitted a longer-duration formulation of Adderall XR to the FDA for approval; and Protox Therapeutics bought a brain cancer drug from Neurocrine. The Centient Biotech 200™ fell 4 points to 3520.49, a decline of .11%. More details...
